Worries Over New Arthritis 'Smart Drug' Monthly Injection

While the media currently feeds a frenzy ofhigher risk of serious infections compared to study
excitement regarding the new arthritis gene therapyparticipants who were treated with methotrexate
drug known as Tocilizumab, Hundreds of thousandsalone or with a combination of a disease modifying
of rheumatoid arthritis sufferers are offered newanti-rheumatic drug and a placebo.
hope in beating there debilitating condition.Reported problems with Tocilizumab in Japan,
The new drug is being heralded as a mile stone inReported Tocilizumab problem on Oct 25, 2005. Male
rheumatoid arthritis treatment following a trial in whichpatient, 34 years of age, was treated with
nearly half of patients on the medication found theirTocilizumab. After the drug was administered, patient
condition did not get any worse. Tocilizumab, whichexperienced the following problems/side effects:
will be sold under the brand name 'Actemra' works inacidosis, alpha haemolytic streptococcal infection,
conjunction with an existing treatment,bacteraemia, brain abscess, candidiasis, cerebral
methotrexate, and is administered monthly in hospital.hemorrhage, dehydration, depressed level of
In the trial, taking methotrexate on its own onlyconsciousness, disseminated tuberculosis.
stopped symptoms in eight per cent ofDosage: unknown.
patients.Combined with Tocilizumab, 47 per cent ofDuring the same period the patient was treated with
patients saw their condition halted. The drug is stillKlaricid, Iscotin, Ethambutol, Hydrochloride, Rifadin
under review in the UK by Nice ( National Institute& Pyrazinamide, following the medication the
for Health and Clinical Excellence) but is it expectedpatient was hospitalized. Patient unfortunately died on
to gain its UK marketing license in January 2009.02/19/2006.
Nice caused some controversy recently by ruling thatAnother reported Tocilizumab problem was reported
rheumatoid arthritis sufferers could not switch fromby a Physician from Japan on Nov 30, 2005. a female
one form of a pain relieving drug to another if thepatient, 53 years old, was diagnosed with rheumatoid
initial treatment did not work. There are fears thatarthritis and was treated with Tocilizumab. After the
Tocilizumab - which could cost up to £10,000drug was administered the patient in question
per annum - may not become available on the NHSexperienced the following side effects: condition
and if it does become available will it be available toaggravated, hyperlipidaemia, hypertension, thalamic
the masses and not just the few.infarction.
Known side effects include diarrhea thalamicTocilizumab dosage: unknown
infarction, hypertension, hyperlipidaemia, vomiting,During the same period the patient was treated with
upper respiratory tract inflammation, ligament rupture,Methotrexate, Predonine, Diclofenac, Misoprostol,
hypoaesthesia, headache, cholelithiasis. gastrointestinalNifedipine, Arotinolol, The patient was hospitalized but
bleeding, gastroenteritis, bronchitis, Pneumonia and alater recovered.
potentially serious bacterial skin infection called cellulitis.These are just a couple of incidents which have been
Concerns have also been expressed in regard ofreported, however many more can be found if you
cholesterol levels apparently Tocilizumab is thought toGoogle Tocilizumab, of course, as with any
raise LDL, which is bad cholesterol, & could putmedication, problems will exist due to their toxicity.
patients at risk of heart attack or stroke.Tocilizumab may be an excellent treatment for some,
Study participants who took Tocilizumab also had abut perhaps not so for others.